Drug
Capivasertib clinical trials
Also written AZD5363 and Truqap.
- studies test it
- 52
- open now
- 13
- in phase 3
- 9
- first study started
- 2010
Keep track of what changes. Save the capivasertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2014 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 9 |
| 2015 | 6 |
| 2016 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 27
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 31
AstraZeneca (21) · National Cancer Institute (NCI) (3) · UNICANCER (2) · Samsung Medical Center (2) · VA Office of Research and Development (2) · Institute of Cancer Research, United Kingdom (2) · M.D. Anderson Cancer Center (1) · Velindre NHS Trust (1)
Often tested with
Tested in the same studies.
Olaparib (8) · Durvalumab (7) · Vistusertib (5) · AZD 6244 (5) · Ceralasertib (5) · AZD4547 (4) · Fulvestrant (4) · Adavosertib (3)
Studies
Open first, then newest update. How each study uses capivasertib is read from its arms, and is right about nine times in ten.
Testing it · 52
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Written as Capivasertib
- Immunotherapy Plus Capivasertib for Metastatic Bladder CancerNot yet recruitingPhase 1/2VA Office of Research and DevelopmentNCT07793578Written as capivasertib
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Written as Capivasertib
- A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruitingPhase 1AstraZenecaNCT07343960Written as Capivasertib
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Capivasertib
- Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruitingPhase 3Women's Cancer Study Group GmbHNCT07281833Written as Capivasertib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Capivasertib
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677Written as Capivasertib
- HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT07175415Written as Capivasertib
- Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingPhase 1National University Hospital, SingaporeNCT03772561Written as AZD5363+Olaparib+Durvalumab
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Capivasertib plus Docetaxel
- Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06607757Written as Capivasertib
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingPhase 2National Taiwan University HospitalNCT05720260Written as Capivasertib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Capivasertib
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03660826Written as Capivasertib
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingPhase 3AstraZenecaNCT06764186Written as Capivasertib
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingPhase 3AstraZenecaNCT04493853Written as Capivasertib
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02208375Written as Capivasertib
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587Written as AZD9833 with capivasertib
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingPhase 3AstraZenecaNCT04862663Written as Capivasertib
See all 52 studies that test capivasertib →
Given in every arm · 7 — capivasertib is usual care beside what is tested
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Written as Capivasertib
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingPhase 1M.D. Anderson Cancer CenterNCT05039801Written as Capivasertib
- Rash & Diarrhea Prophylaxis With CapivasertibRecruitingPhase 2Maryam LustbergNCT07426822Written as Capivasertib
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Written as Capivasertib
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingPhase 1AstraZenecaNCT04556773Written as Capivasertib
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Written as Capivasertib
- AZD5363 in Patients With Advanced Solid Tumors Harboring AKT MutationsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03310541Written as AZD5363
As the comparator · 1 — what is tested is compared with capivasertib
Codes
What other systems call capivasertib · ClinicalTrials.gg INT006151
- MeSH (NLM) C575618capivasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WFR23M21IECAPIVASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27074756capivasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102564CapivasertibOne source FDA
- DrugBank DB12218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575618 | capivasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WFR23M21IE | CAPIVASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074756 | capivasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102564 | Capivasertib | One source FDA |
| DrugBank | DB12218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.